International Journal of Hematology - Top Articles
Volume 119, Number 5- PROGRESS IN HEMATOLOGY -
● Cancer-associated thrombosis and bleeding (by Takayuki Ikezoe)
● The pathogenesis of cancer-associated thrombosis (by Kohei Tatsumi)
● Clinical guidelines for prevention and treatment of CAT in Japan and other countries (by Yoshinobu Seki)
● Cancer-associated thrombosis in hematologic malignancies (by Masahiko Fukatsu & Takayuki Ikezoe)
● Dysregulated hemostasis in acute promyelocytic leukemia (by Yohei Hisada)
Volume 119, Number 3- PROGRESS IN HEMATOLOGY –
● Aplastic anemia: history and recent developments in diagnosis and treatment (by Yasushi Onishi)
● Allogeneic bone marrow transplantation for aplastic anemia (by Rainer Storb)
● Diagnosis of immune pathophysiology in patients with bone marrow failure (by Shinji Nakao)
● Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia (by Nao Yoshida)
● Progress in medical therapy in aplastic anemia: why it took so long? (by Phillip Scheinberg)
Volume 118, Number 2- PROGRESS IN HEMATOLOGY –
● Prophylactic or pre-emptive therapies to prevent relapse after allogeneic hematopoietic stem cell transplantation (by Shinichi Kako)
● Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation (by Kaito Harada)
● Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS (by Yuho Najima)
● Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (by Hideki Nakasone)
● Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma (by Koji Kawamura)
Volume 117, Number 6- PROGRESS IN HEMATOLOGY –
●Stem cell regulation and dynamics in myeloid malignancies (by Goro Sashida)
●Epigenetic regulation by ASXL1 in myeloid malignancies (by Feng-Chun Yang & Joel Agosto-Peña)
● RNA modifications in hematological malignancies (by Zhen Jin, et al.)
● Extracellular vesicle-mediated remodeling of the bone marrow microenvironment in myeloid malignancies (by Yasutaka Hayashi, et al.)
● Childhood hematopoietic stem cells constitute the permissive window for RUNX1-ETO leukemogenesis (by Mohamed Gaber Abdallah, et al.)
Volume 117, Number 5- PROGRESS IN HEMATOLOGY –
●Guest Editorial: what can be done to improve cancer immunotherapies? (by Hideto Tamura)
●Resilient T-cell responses in patients with advanced cancers (by Joanina K. Gicobi, et al.)
●Extracellular vesicle-mediated immunoregulation in cancer (by Tomofumi Yamamoto, et al.)
●Novel technologies for improving the safety and efficacy of CAR-T cell therapy (by Keisuke Ohta, et al.)
●Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy (by Brian M. Russell & David E. Avigan)
Volume 117, Number 4- PROGRESS IN HEMATOLOGY –
●T cell lymphoma: time to make discoveries and advance treatment (by Kenji Ishitsuka)
●Mature T-cell and NK-cell lymphomas: updates on molecular genetic features (by Natasha E. Lewis, et al.)
●Moving towards biologically informed treatment strategies for T-cell lymphomas (by Robert Stuver, et al.)
●Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma (by Jun-ichirou Yasunaga)
●Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma (by Hiroo Katsuya)
Volume 117, Number 3- PROGRESS IN HEMATOLOGY –
●Progress in pathophysiological understanding and treatment of thrombocytopenia (by Hirokazu Kashiwagi )
●Recent progress in ITP treatment (by Francesco Rodeghiero)
●Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura (by Masayuki Kubo & Masanori Matsumoto)
●Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder (by Laura M. Venier, et al.)
●Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets (by Si Jing Chen, et al.)
Volume 117, Number 2- PROGRESS IN HEMATOLOGY –
●Guest editorial: recent progress in pediatric leukemia (by Toshihiko Imamura)
●Recent progress in pediatric lymphoblastic leukemia (by Motohiro Kato)
●Evolution and optimization of therapies for acute lymphoblastic leukemia in infants (by Daisuke Tomizawa)
●Comprehensive molecular understanding of pediatric acute myeloid leukemia (by Norio Shiba)
●Recent progress in the management of pediatric chronic myeloid leukemia (by Haruko Shima & Hiroyuki Shimada)
Volume 117, Number 1- PROGRESS IN HEMATOLOGY –
●Chronic myeloid leukemia: the cutting-edge evidence and things we should know (by Noriyoshi Iriyama)
●Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities (by Zehra Narlı Özdemir,et al.)
●Asciminib as a third line option in chronic myeloid leukemia (by Alessandro Laganà, et al.)
●Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia (by Yoshihiro Umezawa & Koji Sasaki)
●Genetic landscape of chronic myeloid leukemia (by Yotaro Ochi)
Volume 116, Number 6- PROGRESS IN HEMATOLOGY –
●Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target? (by Koji Kato)
●Biological and clinical significance of epigenetic alterations in B-cell lymphomas (by Daisuke Ennishi)
●The role of epigenetics in T-cell lymphoma (by Makoto Yamagishi)
●The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy (by Ying Wang, et al.)
Volume 116, Number 3- PROGRESS IN HEMATOLOGY –
●Guest editorial: prophylaxis and treatment of relapse after allogeneic hematopoietic stem cell transplantation (by Daigo Hashimoto)
●Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review (by Ayumu Ito, et al.)
●Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation (by Xing-yu Cao, et al.)
●Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment (by Firas Kreidieh, et al.)
●FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation (by Francesca Biavasco and Robert Zeiser)
Volume 116, Number 2- PROGRESS IN HEMATOLOGY –
● The path from stem cells to red blood cells (by Hideo Harigae)
● The role of specialized cell cycles during erythroid lineage development: insights from single-cell RNA sequencing (by Merav Socolovsky)
● Heme as a differentiation-regulatory transcriptional cofactor (by Ruiqi Liao and Emery H. Bresnick)
● The mutual crosstalk between iron and erythropoiesis (by Clara Camaschella, et al.)
● Induction of enucleation in primary and immortalized erythroid cells (by Svetlana Soboleva and Kenichi Miharada)
Volume 116, Number 1- PROGRESS IN HEMATOLOGY –
● Guest editorial: current status and future perspectives of allogeneic hematopoietic cell transplantation for non-malignant diseases (by Katsutsugu Umeda)
● Conditioning regimens for inborn errors of immunity: current perspectives and future strategies (by Akira Nishimura, et al.)
● Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes (by Hirotoshi Sakaguchi and Nao Yoshida)
● Allogeneic hematopoietic stem cell transplantation for inherited metabolic disorders (by Hiromasa Yabe)
● Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases (by Katsutsugu Umeda)
Volume 115, Number 6- PROGRESS IN HEMATOLOGY –
● Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma? (by Hiroyuki Takamatsu)
● Multiple myeloma with high-risk cytogenetics and its treatment approach (by Ichiro Hanamura)
● Progress of modern imaging modalities in multiple myeloma (by Toshiki Terao and Kosei Matsue)
● Bringing mass spectrometry into the care of patients with multiple myeloma (by David L. Murray)
● Novel immunotherapies in multiple myeloma (by Ken Ohmine and Ryosuke Uchibori)
Volume 115, Number 5- PROGRESS IN HEMATOLOGY –
● Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options (by Akihiko Gotoh)
● Improving allogeneic stem cell transplantation in myelofibrosis (by Nico Gagelmann and Nicolaus Kröger)
● Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives (by Giuseppe G. Loscocco and Alessandro M. Vannucchi)
● Novel treatments for myelofibrosis: beyond JAK inhibitors (by Douglas Tremblay and Ruben Mesa)
● Treatment options and pregnancy management for patients with PV and ET (by Yoko Edahiro)
Volume 114, Number 5- PROGRESS IN HEMATOLOGY –
● Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells (by Hiroshi Fujiwara)
● Next-generation CAR T cells to overcome current drawbacks (by Stefan Lundh, et al.)
● Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine (by Xiuli Wang, et al.)
● Engineering the next generation of CAR-NK immunotherapies (by Alexander Biederstädt and Katayoun Rezvani)
● Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors (by Tatsuki Ueda and Shin Kaneko)
Volume 113, Number 5- PROGRESS IN HEMATOLOGY –
● Evolution of CML treatment (by Shinya Kimura)
● Current status and novel strategy of CML (by Kiyomi Morita and Koji Sasaki)
● Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia (by Hyewon Lee, et al.)
● Treatment-free remission and immunity in chronic myeloid leukemia (by Hiroshi Ureshino)
● New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism (by Kazuhito Naka)
Volume 113, Number 1- PROGRESS IN HEMATOLOGY –
● Diversity of disseminated intravascular coagulaton and selection of appropriate treatments (by Hidesaku Asakura)
● Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations (by Shinya Yamada and Hidesaku Asakura)
● Recent advances in the research and management of sepsis-associated DIC (by Toshiaki Iba, et al.)
● Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies (by Takayuki Ikezoe)
● COVID-19-associated coagulopathy and disseminated intravascular coagulation (by Hidesaku Asakura and Haruhiko Ogawa)
Volume 111, Number 5- PROGRESS IN HEMATOLOGY –
●Guest editorial: B1 cells: their ontogeny and malignant counterpart (by Naoyuki Katayama)
●The ontogeny of murine B-1a cells (by Momoko Yoshimoto)
●Ontogeny of human B1 cells (by Yuki Kageyama and Naoyuki Katayama)
●Pathophysiology of chronic lymphocytic leukemia and human B1 cell development (by Yoshikane Kikushige)
●Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? (by Junji Suzumiya and Jun Takizawa)
Volume 111, Number 4- PROGRESS IN HEMATOLOGY –
● Introduction by the Guest Editor: Recent advances in biology and treatment of multiple myeloma (by Hirokazu Tanaka)
● Molecular basis of clonal evolution in multiple myeloma (by Yusuke Furukawa and Jiro Kikuchi)
● Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost (by Kenshi Suzuki)
● Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan (by Hiroyuki Takamatsu)
● Chimeric antigen receptor T-cell therapy for multiple myeloma (by Naoki Hosen)
Volume 111, Number 2- PROGRESS IN HEMATOLOGY -
●Progress in elucidation of molecular pathophysiology and its application in therapeutic decision-making for myeloproliferative neoplasms (by Katsuto Takenaka)
●Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions (by Ruochen Jia and Robert Kralovics)
●Mutational profiling in myelofibrosis: implications for management (by Prithviraj Bose and Srdan Verstovsek)
●The role of calreticulin mutations in myeloproliferative neoplasms (by Marito Araki and Norio Komatsu)
●The role of driver mutations in myeloproliferative neoplasms: insights from mouse models (by Kotaro Shide)
Volume 111, Number 1- PROGRESS IN HEMATOLOGY -
●Current progress and future direction in the treatment for hemophilia (by Midori Shima)
●Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity (by Takehisa Kitazawa and Midori Shima)
●Advances in gene therapy for hemophilia: basis, current status, and future perspectives (by Tsukasa Ohmori)
●Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia (by Pratima Chowdary)
Volume 110, Number 2- PROGRESS IN HEMATOLOGY -
●Epigenetic abnormalities and therapies for hematological malignancies (by Toshio Kitamura)
●New insights into the biology of acute myeloid leukemia with mutated NPM1 (by Lorenzo Brunetti, et al.)
●Clinical update on hypomethylating agents (by Matthieu Duchmann and Raphael Itzykson)
●Deregulated Polycomb functions in myeloproliferative neoplasms (by Goro Sashida, et al.)
●Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms (by Shuhei Asada and Toshio Kitamura)
Volume 110, Number 1- PROGRESS IN HEMATOLOGY -
●Guest Editorial: Are “alternative” stem cell sources still alternative in the new era? (by Junya Kana)
●Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation (by Koji Kawamura)
●HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide (by Junichi Sugita)
●Single cord blood transplantation in Japan; expanding the possibilities of CBT (by Hisashi Yamamoto)
●Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells (by Ko K. Maung and Mitchell E. Horwitz)
Volume 109, Number 1- PROGRESS IN HEMATOLOGY -
●Molecular pathogenesis of leukemia and leukemic stem cells (LSCs) (by Masahiro Kizaki)
●Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia (by Tze King Tan, et al.)
●Metabolism as master of hematopoietic stem cell fate (by Kyoko Ito, et al.)
●Targeting transcription factors in acute myeloid leukemia (by Hisashi Takei and Susumu S. Kobayashi)
●What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells (by Nathalia Azevedo Portilho, et al.)